Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:10/5/2009

tion ever. We finally have the financial resources to move forward on our programs. Our manufacturing facility is coming online, the global Phase III cancer trial for Multikine is being launched together with Teva Pharmaceuticals and Orient EuroPharma as two of our main partners, and we are racing to develop what we hope to be the first effective treatment for hospitalized H1N1 patients. We will continue to keep you up-to-date with any further material developments.

We thank you for your support as we move forward in several key areas.

Sincerely,

Geert Kersten

Chief Executive Officer

For more information, please visit www.cel-sci.com.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, lack of regulatory clearance to proceed with clinical trials, an inability to duplicate the clinical results demonstrated in clinical studies that have been completed or that are initiated in the future, timely development of any potential products that can be shown to be safe and effective, unwillingness of regulatory authorities to engage in further regulatory dialogue, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
2. CEL-SCI Expands H1N1 Flu Virus Work
3. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
4. CEL-SCI Posts New Corporate Presentation to Website
5. CEL-SCI Corporation Releases Letter to Shareholders
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
8. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
9. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Corporation Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... , Sept. 17, 2014  Dr. Stephen ... the White House today for National Recovery Month, stars ... consumer advocates released today. Consumer advocates were also joined ... who spoke out after losing her fiancée because of ... the doctor had a history of crack cocaine abuse. ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire-iReach/ -- ChemImage announced ... discussing improvements in the development of imaging ... both normal and diseased tissue that minimizes ... surgical procedures, lowers surgical costs and potentially ... The clinical and scientific ...
Breaking Medicine Technology:Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2
... 4 Novartis Vaccines & Diagnostics Inc. and Novartis ... to resolve civil False Claims Act allegations arising from the ... announced today. The settlement resolves allegations that, between Jan. ... and its predecessor, Chiron Corporation, caused false claims to be ...
... Joseph F. Finn, Jr. , C.P.A. ("Finn"),  Assignee for ... that the MRI imaging intellectual properties of the EP-3600 MRI imaging ... assets of Epix were transferred to him on July 20, ... Epix creditors.  He recently reached an agreement with Bayer Schering Pharma ...
Cached Medicine Technology:Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI 2Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI 3Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent 2
(Date:9/17/2014)... Dallas, TX (PRWEB) September 17, 2014 ... they were recently granted several awards for their top-notch ... regarding patient experience, orthopedic care and GYN surgery. , ... Patient Safety Excellence Award™. They have received this award ... ranked among the top 5 percent in the nation ...
(Date:9/17/2014)... News, VA (PRWEB) September 17, 2014 ... will host recruit757’s scholarship workshop for football players ... on Tuesday, Sept. 23. , Doors open at 6:30 ... Performance Center and speak to trainers and physical therapists. ... until 9 p.m. , The Newport News Tidewater Performance ...
(Date:9/17/2014)... messages about the health benefits of quitting smoking may ... suggests. Although smokers who think quitting will be ... effects of smoking, researchers found smokers who believe they ... or positive, messages about how quitting will improve their ... of both types of messages might get more people ...
(Date:9/17/2014)... September 17, 2014 Prevention is the ... is hospitalizing scores of infants, children and teenagers in ... Kirk Mahon, medical director of Legacy ER & Urgent ... been no reported cases of EV-D68 so far in ... that could change,” he said. “Implementing prevention strategies now ...
(Date:9/17/2014)... 17, 2014 Boston Children’s Museum ... a monthly concert series, introducing young Museum visitors ... Top, America’s premier national platform celebrating the stories, ... of the young musicians featured will also be ... Children’s Museum is fortunate to partner with the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... News) -- Body-building and weight-loss products are the types of ... a small new study. Liver injury from medication is ... and herbal supplements -- which do not require a prescription ... are used by up to 40 percent of people in ...
... (ICUs) that have no or limited access to critical care ... the specialists, called intensivists, staff the unit at night, according ... Pittsburgh School of Medicine and UPMC. However, the researchers were ... ICUs that were robustly staffed with the specialists during the ...
... Va. (May 22, 2012) The Food and Drug Administration ... group of rare cell disorders. The test, or assay, was ... field of mast cells. Lawrence Schwartz, M.D., Ph.D., chair ... Charles and Evelyn Thomas Professor of Medicine at VCU, has ...
... , TUESDAY, May 22 (HealthDay News) -- Got hair? If ... cancer, a preliminary study suggests. Researchers are reporting ... more likely to have cancer than were those with more ... that they may benefit from being screened earlier and perhaps, ...
... are not effective in determining which asthma patients are ... (ICS) medications without risk of flare-ups or exacerbations, according ... United Kingdom. The study also showed that nearly three-quarters ... use of ICS medications once their symptoms are under ...
... The new blood thinner Xarelto appears to lower the chances ... U.S. Food and Drug Administration review has found. The ... advance of an FDA advisory panel meeting Wednesday, at which ... of Xarelto for treating people with acute coronary syndrome (a ...
Cached Medicine News:Health News:Body Building, Diet Supplements Linked to Liver Damage: Study 2Health News:Intensivists at night improve patient outcomes in some ICUs, says Pitt/UPMC team 2Health News:FDA clears test developed in partnership with VCU researcher 2Health News:Do Bald Men Face Higher Risk of Prostate Cancer? 2Health News:Do Bald Men Face Higher Risk of Prostate Cancer? 3Health News:Identifying asthma patients who tolerate lower doses of steroids remains problematic 2Health News:Identifying asthma patients who tolerate lower doses of steroids remains problematic 3Health News:New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: